BRNS
Barinthus Biotherapeutics plc (BRNS) SWOT Analysis Analysis (2026)
Strengths
Negative cash conversion cycle of -110.8 days indicates BRNS collects cash well before paying suppliers, supporting liquidity versus peers with longer working-capital cycles.
Current and quick ratios of 5.5x suggest unusually strong near-term liquidity, reducing refinancing pressure relative to more levered small-cap peers.
Debt-to-equity of 0.18x remains modest, implying balance-sheet flexibility versus peers that rely more heavily on leverage to fund operations.
Weaknesses
ROIC of -61.1% shows capital is currently destroying value, leaving BRNS structurally weaker than profitable peers that compound invested capital.
Net debt to EBITDA of 1.3x is manageable but still constrains flexibility versus net-cash peers, especially given the absence of demonstrated earnings power.
Missing margin disclosure alongside negative ROIC suggests limited operating efficiency visibility, which weakens comparability against peers with stable margin profiles.
Opportunities
If BRNS converts its strong working-capital profile into sustained earnings, peers with weaker cash cycles would face a structural disadvantage in funding growth.
Low leverage leaves room for operational scaling without immediate balance-sheet stress, unlike more indebted peers that must prioritize deleveraging.
Improving capital efficiency from a deeply negative ROIC base could create outsized relative upside if management closes the gap with profitable peers.
Threats
Persistently negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest at higher rates and widen the performance gap.
Any deterioration in cash conversion would quickly pressure liquidity, since BRNS currently depends on an unusually favorable working-capital structure versus peers.
Without visible margin strength, peers with better pricing power or cost discipline may sustain superior economics and erode BRNS's relative positioning.
Overall Score
BRNS shows balance-sheet and working-capital resilience, but deeply negative capital returns keep its structural positioning below stronger, profitable peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Barinthus Biotherapeutics plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

